| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 10. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | idarucizumab (Praxbind®) |
| Formulation | 2.5g/50mL intravenous infusion |
| Reference number | 2670 |
| Indication | As a specific reversal agent for dabigatran and is indicated in adult patients treated with Pradaxa (dabigatran etexilate) when rapid reversal of its anticoagulant effects are required: for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding |
| Company | Boehringer Ingelheim Ltd |
| BNF chapter | Cardiovascular system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 22/10/2015 |